{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:21:35Z","timestamp":1794471695313,"version":"4.9.1"},"reference-count":69,"publisher":"American Society of Hematology","issue":"21","license":[{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,12]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Hematologic toxicity is a common side effect of chimeric antigen receptor T-cell (CAR-T) therapies, being particularly severe among patients with relapsed or refractory multiple myeloma (MM). In this study, we characterized 48 patients treated with B-cell maturation antigen (BCMA) CAR-T cells to understand kinetics of cytopenia, identify predictive factors, and determine potential mechanisms underlying these toxicities. We observed that overall incidence of cytopenia was 95.7%, and grade &amp;gt;3 thrombocytopenia and neutropenia, 1\u00a0month after infusion, was observed in 57% and 53% of the patients, respectively, being still present after 1 year in 4 and 3 patients, respectively. Baseline cytopenia and high peak inflammatory markers were highly correlated with cytopenia that persisted up to 3\u00a0months. To determine potential mechanisms underlying cytopenias, we evaluated the paracrine effect of BCMA CAR-T cells on hematopoietic stem and progenitor cell (HSPC) differentiation using an ex vivo myeloid differentiation model. Phenotypic analysis showed that supernatants from activated CAR-T cells (spCAR) halted HSPC differentiation, promoting more immature phenotypes, which could be prevented with a combination of interferon \u03b3, tumor necrosis factor \u03b1\/\u03b2, transforming growth factor \u03b2, interleukin-6 (IL-6) and IL-17 inhibitors. Single-cell RNA sequencing demonstrated upregulation of transcription factors associated with early stages of hematopoietic differentiation in the presence of spCAR (GATA2, RUNX1, CEBPA) and a decrease in the activity of key regulons involved in neutrophil and monocytic maturation (ID2 and MAFB). These results suggest that CAR-T activation induces HSPC maturation arrest through paracrine effects and provides potential treatments to mitigate the severity of this toxicity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023012522","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T16:09:29Z","timestamp":1722010169000},"page":"5479-5492","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":28,"title":["Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in multiple myeloma"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2894-4703","authenticated-orcid":false,"given":"Maria Luisa","family":"Palacios-Berraquero","sequence":"first","affiliation":[{"name":"1Hematology and Cell Therapy Department, Cancer Center Clinica Universidad de Navarra, IdiSNA, Pamplona, Spain"},{"name":"3Centro de Investigacion Biomedica en Red de Cancer, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9812-396X","authenticated-orcid":false,"given":"Paula","family":"Rodriguez-Marquez","sequence":"additional","affiliation":[{"name":"2Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain"},{"name":"3Centro de Investigacion Biomedica en Red de Cancer, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0688-0793","authenticated-orcid":false,"given":"Maria Erendira","family":"Calleja-Cervantes","sequence":"additional","affiliation":[{"name":"2Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain"},{"name":"4Computational Biology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9868-0547","authenticated-orcid":false,"given":"Nerea","family":"Berastegui","sequence":"additional","affiliation":[{"name":"2Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain"},{"name":"3Centro de Investigacion Biomedica en Red de Cancer, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aintzane","family":"Zabaleta","sequence":"additional","affiliation":[{"name":"3Centro de Investigacion Biomedica en Red de Cancer, Madrid, Spain"},{"name":"5Flow Cytometry Core, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0998-2496","authenticated-orcid":false,"given":"Leire","family":"Burgos","sequence":"additional","affiliation":[{"name":"3Centro de Investigacion Biomedica en Red de Cancer, Madrid, Spain"},{"name":"5Flow Cytometry Core, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Alignani","sequence":"additional","affiliation":[{"name":"3Centro de Investigacion Biomedica en Red de Cancer, Madrid, Spain"},{"name":"5Flow Cytometry Core, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1483-4279","authenticated-orcid":false,"given":"Patxi","family":"San Martin-Uriz","sequence":"additional","affiliation":[{"name":"2Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain"},{"name":"3Centro de Investigacion Biomedica en Red de Cancer, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6693-0989","authenticated-orcid":false,"given":"Amaia","family":"Vilas-Zornoza","sequence":"additional","affiliation":[{"name":"1Hematology and Cell Therapy Department, Cancer Center Clinica Universidad de Navarra, IdiSNA, Pamplona, Spain"},{"name":"3Centro de Investigacion Biomedica en Red de Cancer, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saray","family":"Rodriguez-Diaz","sequence":"additional","affiliation":[{"name":"2Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain"},{"name":"3Centro de Investigacion Biomedica en Red de Cancer, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9370-8416","authenticated-orcid":false,"given":"Susana","family":"Inoges","sequence":"additional","affiliation":[{"name":"1Hematology and Cell Therapy Department, Cancer Center Clinica Universidad de Navarra, IdiSNA, Pamplona, Spain"},{"name":"3Centro de Investigacion Biomedica en Red de Cancer, Madrid, Spain"},{"name":"6Immunology and Immunotherapy Department, Clinica Universidad de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ascensi\u00f3n","family":"Lopez-Diaz de Cerio","sequence":"additional","affiliation":[{"name":"1Hematology and Cell Therapy Department, Cancer Center Clinica Universidad de Navarra, IdiSNA, Pamplona, Spain"},{"name":"3Centro de Investigacion Biomedica en Red de Cancer, Madrid, Spain"},{"name":"6Immunology and Immunotherapy Department, Clinica Universidad de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Huerga","sequence":"additional","affiliation":[{"name":"1Hematology and Cell Therapy Department, Cancer Center Clinica Universidad de Navarra, IdiSNA, Pamplona, Spain"},{"name":"3Centro de Investigacion Biomedica en Red de Cancer, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4088-0992","authenticated-orcid":false,"given":"Esteban","family":"Tamariz","sequence":"additional","affiliation":[{"name":"1Hematology and Cell Therapy Department, Cancer Center Clinica Universidad de Navarra, IdiSNA, Pamplona, Spain"},{"name":"3Centro de Investigacion Biomedica en Red de Cancer, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1649-8478","authenticated-orcid":false,"given":"Jose","family":"Rifon","sequence":"additional","affiliation":[{"name":"1Hematology and Cell Therapy Department, Cancer Center Clinica Universidad de Navarra, IdiSNA, Pamplona, Spain"},{"name":"3Centro de Investigacion Biomedica en Red de Cancer, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2478-5354","authenticated-orcid":false,"given":"Ana","family":"Alfonso-Pierola","sequence":"additional","affiliation":[{"name":"1Hematology and Cell Therapy Department, Cancer Center Clinica Universidad de Navarra, IdiSNA, Pamplona, Spain"},{"name":"3Centro de Investigacion Biomedica en Red de Cancer, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jose","family":"Lasarte","sequence":"additional","affiliation":[{"name":"7Immunology and Immunotherapy Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1977-3815","authenticated-orcid":false,"given":"Bruno","family":"Paiva","sequence":"additional","affiliation":[{"name":"2Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain"},{"name":"3Centro de Investigacion Biomedica en Red de Cancer, Madrid, Spain"},{"name":"5Flow Cytometry Core, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0443-2305","authenticated-orcid":false,"given":"Mikel","family":"Hernaez","sequence":"additional","affiliation":[{"name":"3Centro de Investigacion Biomedica en Red de Cancer, Madrid, Spain"},{"name":"4Computational Biology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain"},{"name":"8Data Science and Artificial Intelligence Institute, Universidad de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5236-7785","authenticated-orcid":false,"given":"Paula","family":"Rodriguez-Otero","sequence":"additional","affiliation":[{"name":"1Hematology and Cell Therapy Department, Cancer Center Clinica Universidad de Navarra, IdiSNA, Pamplona, Spain"},{"name":"3Centro de Investigacion Biomedica en Red de Cancer, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9183-4857","authenticated-orcid":false,"given":"Jesus","family":"San-Miguel","sequence":"additional","affiliation":[{"name":"1Hematology and Cell Therapy Department, Cancer Center Clinica Universidad de Navarra, IdiSNA, Pamplona, Spain"},{"name":"3Centro de Investigacion Biomedica en Red de Cancer, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3682-7125","authenticated-orcid":false,"given":"Teresa","family":"Ezponda","sequence":"additional","affiliation":[{"name":"2Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain"},{"name":"3Centro de Investigacion Biomedica en Red de Cancer, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4327-1866","authenticated-orcid":false,"given":"Juan Roberto","family":"Rodriguez-Madoz","sequence":"additional","affiliation":[{"name":"2Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain"},{"name":"3Centro de Investigacion Biomedica en Red de Cancer, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6115-8790","authenticated-orcid":false,"given":"Felipe","family":"Prosper","sequence":"additional","affiliation":[{"name":"1Hematology and Cell Therapy Department, Cancer Center Clinica Universidad de Navarra, IdiSNA, Pamplona, Spain"},{"name":"2Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain"},{"name":"3Centro de Investigacion Biomedica en Red de Cancer, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"issue":"1","key":"2024111213403047500_bib1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"2024111213403047500_bib2","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2024111213403047500_bib3","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2024111213403047500_bib4","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"issue":"6","key":"2024111213403047500_bib5","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.clml.2019.12.026","article-title":"Treatment options for triple-class refractory multiple myeloma","volume":"20","author":"Mikhael","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"2024111213403047500_bib6","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2024111213403047500_bib7","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2024111213403047500_bib8","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"10297","key":"2024111213403047500_bib9","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"26","key":"2024111213403047500_bib10","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1182\/blood-2017-04-778423","article-title":"SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes","volume":"130","author":"Gogishvili","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2024111213403047500_bib11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"2024111213403047500_bib12","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"2024111213403047500_bib13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"issue":"23","key":"2024111213403047500_bib14","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 2","key":"2024111213403047500_bib15","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41409-019-0602-5","article-title":"Insight into mechanisms associated with cytokine release syndrome and neurotoxicity after CD19 CAR-T cell immunotherapy","volume":"54","author":"Chou","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2024111213403047500_bib16","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","article-title":"Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematol","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann Oncol"},{"issue":"3","key":"2024111213403047500_bib17","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41409-020-01134-4","article-title":"Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL","volume":"56","author":"Sheth","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2024111213403047500_bib18","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/s41409-022-01756-w","article-title":"Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy","volume":"57","author":"Wudhikarn","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2024111213403047500_bib19","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.3324\/haematol.2020.254045","article-title":"Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma","volume":"106","author":"Strati","year":"2021","journal-title":"Haematologica"},{"issue":"26","key":"2024111213403047500_bib20","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024111213403047500_bib21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"7","key":"2024111213403047500_bib22","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/bloodadvances.2020004142","article-title":"Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy","volume":"6","author":"Juluri","year":"2022","journal-title":"Blood Adv"},{"issue":"24","key":"2024111213403047500_bib23","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.1182\/bloodadvances.2022008320","article-title":"Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma","volume":"6","author":"Logue","year":"2022","journal-title":"Blood Adv"},{"issue":"10","key":"2024111213403047500_bib24","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and late hematologic toxicity following CD19 CAR-T cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"2024111213403047500_bib25","article-title":"Prolonged hematological toxicity in patients receiving BCMA\/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"issue":"24","key":"2024111213403047500_bib26","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell\u2013related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"issue":"39","key":"2024111213403047500_bib27","doi-asserted-by":"crossref","first-page":"eabo0514","DOI":"10.1126\/sciadv.abo0514","article-title":"CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome","volume":"8","author":"Rodriguez-Marquez","year":"2022","journal-title":"Sci Adv"},{"issue":"1","key":"2024111213403047500_bib28","doi-asserted-by":"crossref","first-page":"7619","DOI":"10.1038\/s41467-022-35192-7","article-title":"The transcription factor DDIT3 is a potential driver of dyserythropoiesis in myelodysplastic syndromes","volume":"13","author":"Berastegui","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"2024111213403047500_bib29","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s42003-022-03319-7","article-title":"SimiC enables the inference of complex gene regulatory dynamics across cell phenotypes","volume":"5","author":"Peng","year":"2022","journal-title":"Commun Biol"},{"issue":"12","key":"2024111213403047500_bib30","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy","volume":"27","author":"Van Oekelen","year":"2021","journal-title":"Nat Med"},{"issue":"4","key":"2024111213403047500_bib31","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"issue":"6472","key":"2024111213403047500_bib32","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1126\/science.aax9198","article-title":"A\u00a0genome-wide transcriptomic analysis of protein-coding genes in human blood cells","volume":"366","author":"Uhlen","year":"2019","journal-title":"Science"},{"issue":"31","key":"2024111213403047500_bib33","doi-asserted-by":"crossref","first-page":"eabh2169","DOI":"10.1126\/sciadv.abh2169","article-title":"A\u00a0single\u2013cell type transcriptomics map of human tissues","volume":"7","author":"Karlsson","year":"2021","journal-title":"Sci Adv"},{"key":"2024111213403047500_bib34","doi-asserted-by":"crossref","first-page":"1.30.1","DOI":"10.1002\/cpbi.5","article-title":"The GeneCards suite: from gene data mining to disease genome sequence analyses","volume":"54","author":"Stelzer","year":"2016","journal-title":"Curr Protoc Bioinformatics"},{"key":"2024111213403047500_bib35","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.exphem.2018.09.004","article-title":"The Human Cell Atlas bone marrow single-cell interactive web portal","volume":"68","author":"Hay","year":"2018","journal-title":"Exp Hematol"},{"issue":"21","key":"2024111213403047500_bib36","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1093\/nar\/gkz789","article-title":"cellHarmony: cell-level matching and holistic comparison of single-cell transcriptomes","volume":"47","author":"DePasquale","year":"2019","journal-title":"Nucleic Acids Res"},{"issue":"18","key":"2024111213403047500_bib37","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood-2016-01-688887","article-title":"Neutrophil heterogeneity: implications for homeostasis and pathogenesis","volume":"127","author":"Silvestre-Roig","year":"2016","journal-title":"Blood"},{"key":"2024111213403047500_bib38","first-page":"8016254","article-title":"Different faces for different places: heterogeneity of neutrophil phenotype and function","volume":"2019","author":"Yang","year":"2019","journal-title":"J\u00a0Immunol Res"},{"key":"2024111213403047500_bib39","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3389\/fimmu.2019.00346","article-title":"Neutrophil heterogeneity as therapeutic opportunity in immune-mediated disease","volume":"10","author":"Grieshaber-Bouyer","year":"2019","journal-title":"Front Immunol"},{"issue":"21","key":"2024111213403047500_bib40","doi-asserted-by":"crossref","first-page":"7492","DOI":"10.1074\/jbc.RA120.012366","article-title":"Inducible expression of a disease-associated ELANE mutation impairs granulocytic differentiation, without eliciting an unfolded protein response","volume":"295","author":"Garg","year":"2020","journal-title":"J\u00a0Biol Chem"},{"issue":"9","key":"2024111213403047500_bib41","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1038\/s41590-020-0736-z","article-title":"Single-cell transcriptome profiling reveals neutrophil heterogeneity in homeostasis and infection","volume":"21","author":"Xie","year":"2020","journal-title":"Nat Immunol"},{"issue":"6","key":"2024111213403047500_bib42","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1007\/s12185-013-1347-3","article-title":"A\u00a0role for RUNX1 in hematopoiesis and myeloid leukemia","volume":"97","author":"Ichikawa","year":"2013","journal-title":"Int J Hematol"},{"issue":"5","key":"2024111213403047500_bib43","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/s41375-022-01548-7","article-title":"Myeloid neoplasms and clonal hematopoiesis from the RUNX1 perspective","volume":"36","author":"Hayashi","year":"2022","journal-title":"Leukemia"},{"issue":"15","key":"2024111213403047500_bib44","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1182\/blood-2016-09-687871","article-title":"The GATA factor revolution in hematology","volume":"129","author":"Katsumura","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2024111213403047500_bib45","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1182\/bloodadvances.2021004311","article-title":"Gata2 19.5 enhancer regulates adult hematopoietic stem cell self-renewal and T-cell development","volume":"6","author":"You","year":"2022","journal-title":"Blood Adv"},{"issue":"10","key":"2024111213403047500_bib46","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1182\/blood.V89.10.3636","article-title":"Transcription factor GATA-2 is required for proliferation\/survival of early hematopoietic cells and mast cell formation, but not for erythroid and myeloid terminal differentiation","volume":"89","author":"Tsai","year":"1997","journal-title":"Blood"},{"issue":"suppl 2","key":"2024111213403047500_bib47","doi-asserted-by":"crossref","first-page":"e12949","DOI":"10.1111\/eci.12949","article-title":"CXCR4, the master regulator of neutrophil trafficking in homeostasis and disease","volume":"48 suppl 2","author":"De Filippo","year":"2018","journal-title":"Eur J Clin Invest"},{"issue":"19","key":"2024111213403047500_bib48","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1182\/blood-2008-09-177287","article-title":"CXCR4 is a key regulator of neutrophil release from the bone marrow under basal and stress granulopoiesis conditions","volume":"113","author":"Eash","year":"2009","journal-title":"Blood"},{"issue":"15","key":"2024111213403047500_bib49","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1182\/blood-2016-09-687822","article-title":"Expression and regulation of C\/EBP\u03b1 in normal myelopoiesis and in malignant transformation","volume":"129","author":"Avellino","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2024111213403047500_bib50","first-page":"329","article-title":"Induction of CD14 expression and differentiation to monocytes or mature macrophages in promyelocytic cell lines: new approach","volume":"3","author":"Zamani","year":"2013","journal-title":"Adv Pharm Bull"},{"issue":"6","key":"2024111213403047500_bib51","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nri.2017.28","article-title":"Monocyte differentiation and antigen-presenting functions","volume":"17","author":"Jakubzick","year":"2017","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"2024111213403047500_bib52","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/MOH.0000000000000647","article-title":"Proteomic\/transcriptomic analysis of erythropoiesis","volume":"28","author":"Brand","year":"2021","journal-title":"Curr Opin Hematol"},{"issue":"7694","key":"2024111213403047500_bib53","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nature25741","article-title":"Population snapshots predict early haematopoietic and erythroid hierarchies","volume":"555","author":"Tusi","year":"2018","journal-title":"Nature"},{"issue":"9","key":"2024111213403047500_bib54","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1084\/jem.20130624","article-title":"RHEX, a novel regulator of human erythroid progenitor cell expansion and erythroblast development","volume":"211","author":"Verma","year":"2014","journal-title":"J\u00a0Exp Med"},{"issue":"2","key":"2024111213403047500_bib55","first-page":"841","article-title":"Proto-oncogenes of the fos\/jun family of transcription factors are positive regulators of myeloid differentiation","volume":"13","author":"Lord","year":"1993","journal-title":"Mol Cell Biol"},{"issue":"11","key":"2024111213403047500_bib56","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1182\/blood-2004-12-4883","article-title":"Differential regulation of granulopoiesis by the basic helix-loop-helix transcriptional inhibitors Id1 and Id2","volume":"105","author":"Buitenhuis","year":"2005","journal-title":"Blood"},{"issue":"2","key":"2024111213403047500_bib57","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.immuni.2018.02.002","article-title":"Developmental analysis of bone marrow neutrophils reveals populations specialized in expansion, trafficking, and effector functions","volume":"48","author":"Evrard","year":"2018","journal-title":"Immunity"},{"issue":"9","key":"2024111213403047500_bib58","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41590-021-00968-4","article-title":"Distinct transcription factor networks control neutrophil-driven inflammation","volume":"22","author":"Khoyratty","year":"2021","journal-title":"Nat Immunol"},{"issue":"6","key":"2024111213403047500_bib59","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.cellsig.2012.02.007","article-title":"Regulation of C\/EBP\u03b2 and resulting functions in cells of the monocytic lineage","volume":"24","author":"Huber","year":"2012","journal-title":"Cell Signal"},{"issue":"9","key":"2024111213403047500_bib60","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1093\/emboj\/19.9.1987","article-title":"MafB is an inducer of monocytic differentiation","volume":"19","author":"Kelly","year":"2000","journal-title":"EMBO J"},{"issue":"9","key":"2024111213403047500_bib61","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2007-10-116343","article-title":"The MADS transcription factor Mef2c is a pivotal modulator of myeloid cell fate","volume":"111","author":"Sch\u00fcler","year":"2008","journal-title":"Blood"},{"issue":"3","key":"2024111213403047500_bib62","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1189\/jlb.72.3.580","article-title":"IL-13 signal transduction in human monocytes: phosphorylation of receptor components, association with Jaks, and phosphorylation\/activation of Stats","volume":"72","author":"Roy","year":"2002","journal-title":"J\u00a0Leukoc Biol"},{"issue":"7","key":"2024111213403047500_bib63","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/bloodadvances.2020004079","article-title":"Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy","volume":"6","author":"Kambhampati","year":"2022","journal-title":"Blood Adv"},{"key":"2024111213403047500_bib64","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3389\/fimmu.2016.00487","article-title":"Stress and non-stress roles of inflammatory signals during HSC emergence and maintenance","volume":"7","author":"Clapes","year":"2016","journal-title":"Front Immunol"},{"issue":"6","key":"2024111213403047500_bib65","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.3390\/cells10061386","article-title":"Inflammation, aging and hematopoiesis: a complex relationship","volume":"10","author":"Bousounis","year":"2021","journal-title":"Cells"},{"issue":"1","key":"2024111213403047500_bib66","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13045-017-0401-7","article-title":"Studying hematopoiesis using single-cell technologies","volume":"10","author":"Ye","year":"2017","journal-title":"J\u00a0Hematol Oncol"},{"issue":"1","key":"2024111213403047500_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2011.04.007","article-title":"The role of the GATA2 transcription factor in normal and malignant hematopoiesis","volume":"82","author":"Vicente","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10","key":"2024111213403047500_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0320-5","article-title":"Interleukin-6 signaling regulates hematopoietic stem cell emergence","volume":"51","author":"Tie","year":"2019","journal-title":"Exp Mol Med"},{"issue":"1","key":"2024111213403047500_bib69","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40164-021-00209-2","article-title":"Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy","volume":"10","author":"Zhang","year":"2021","journal-title":"Exp Hematol Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/21\/5479\/2312568\/blooda_adv-2023-012522-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/21\/5479\/2312568\/blooda_adv-2023-012522-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T08:41:04Z","timestamp":1731400864000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/21\/5479\/517179\/Molecular-mechanisms-promoting-long-term-cytopenia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":69,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2024,11,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023012522","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.05.22.24307750","asserted-by":"object"}]},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,23]]}}}